Drug Trial Radar · NCT05578053
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Sep 13, 2024
Primary completion
Dec 1, 2028
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- Hebei Medical University Fourth HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 13, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, observational, real-world study. We planned to recruit 420 HR+ locally advanced or metastatic breast cancer patients who had received or had not received prior systemic therapy. All patients included in the analysis were receiving or planning to receive dalpiciclib-containing regimens without restrictions, completely following the physician 's clinical choice, to assess the efficacy and safety of dalpiciclib-containing regimens.
Conditions
- Breast Cancer
Interventions
DalpiciclibDrug
a new, orally administered, selective CDK4/6 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: 2 years
- AETime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fourth hospital of Hebei University
Shijiazhuang, Hebei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.